Lancet Respirat Med: The effects of aspirin on sepsis-related deaths in healthy older adults.

Sepsis is a serious global health problem and a leading cause of death and disability.
provide a simple, community-based prevention strategy that can significantly reduce the burden of sepsis.
study (ANTISEPSIS) aims to determine whether low-dose aspirin can reduce sepsis-related deaths or hospitalization in older adults.
ANTISEPSIS is a sub-study of the ASPREE study (preventive effects of taking low-dose aspirin in older adults, 100 mg/day), which included subjects in the Australian queue, including older people aged 70 and over without major illnesses.
grouped subjects randomly (1:1) and hierarchized by general practice and age.
end of the disease is sepsis-related death.
March 10, 2010 - December 24, 2014, a total of 20,288 individuals were evaluated, of whom 16,703 met the requirements were included in the study, with a medium follow-up of 4.6 years (range 3.6-5.6 years).
8,322 patients (49.8 percent) received aspirin prevention and 8,381 took a placebo.
203 deaths were found to be related to sepsis.
multivariate analysis showed similar sepsis-related mortality rates in the aspirin group and the placebo group (Aspirin vs. placebo, HR 1.08, 95% CI 0.82-1.43, p=0.57).
adverse reactions are consistent with stories reported in the ASPREE study.
, low-dose aspirin therapy does not reduce sepsis-related deaths in the elderly of community residents.
study does not support the use of aspirin as a basic predictive strategy to reduce sepsis in this population.
.